Clinical Trial Finder

Inclusion Criteria:

• - Histologically confirmed CNS malignancy at original diagnosis or relapse.

• - Histologic confirmation not required for patients with intrinsic brain stem tumors, optic pathway gliomas, or pineal tumors provided CSF or serum tumor markers, including alpha-fetoprotein orbeta-HCG, are elevated.

• - Recurrent or refractory spinal cord tumors allowed.

• - Measurable or evaluable disease.

• - No known curative therapy or therapy proven to prolong survival with an acceptable quality of life.

• - Karnofsky performance status (PS) 50-100% (for patients > 16 years of age) OR Lansky PS 50-100% (for patients ≤ 16 years of age) - Neurological deficits must have been relatively stable for ≥ 1 week before study entry.

• - Patients unable to walk due to paralysis, but who are up in a wheelchair, are considered ambulatory for the purpose of assessing performance status.

• - ANC ≥ 1,000/μL.

• - Platelet count ≥ 100,000/μL (transfusion independent, defined as no platelet transfusion within the past 7 days) - Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed) - Creatinine clearance or radioisotope GFR ≥ 70mL/min OR maximum serum creatinine based on age and/or gender as follows: - 0.6 mg/dL (1 year of age) - 0.8 mg/dL (2 to 5 years of age) - 1.0 mg/dL (6 to 9 years of age) - 1.2 mg/dL (10 to 12 years of age) - 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years of age) - 1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years of age) - Bilirubin ≤ 1.5 times upper limit of normal.

• - ALT ≤ 110 U/L.

• - Serum albumin ≥ 2 g/dL.

• - Not pregnant or nursing.

• - Negative pregnancy test.

• - Fertile patients must use effective contraception.

• - Able to swallow capsules or liquid.

• - Seizure disorder allowed provided it is well controlled with nonenzyme-inducing anticonvulsants.

• - No pre-existing QTc ≥ 450 msec.

• - No uncontrolled infection.

• - No patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of study.

• - Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy.

• - More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea) - At least 7 days since prior hematopoietic growth factors.

• - At least 7 days since prior biologic agent (antineoplastic agent) - At least 7 days or 3 half-lives, whichever is longer, since prior monoclonal antibodies.

• - More than 2 weeks since prior local palliative radiotherapy (small port) - At least 6 months since prior total-body radiotherapy (TBI), craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis.

• - At least 6 weeks since other prior substantial bone marrow radiotherapy.

• - At least 3 months since prior stem cell transplantation or rescue (without TBI) - No evidence of active graft-vs-host disease.

• - At least 2 weeks since prior valproic acid.

• - No prior vorinostat.

• - Prior temozolomide allowed provided there was no progressive disease during or within 1 month after completion of treatment.

• - Concurrent corticosteroids allowed provided patient has been on a stable or decreasing dose for ≥ 7 days before study entry.

• - No other concurrent investigational drugs.

• - No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy.

- No concurrent enzyme-inducing anticonvulsants

PRIMARY OBJECTIVES:

• I. To estimate the maximum tolerated dose and/or recommended phase II dose of vorinostat in combination with temozolomide in pediatric patients with relapsed or refractory primary CNS tumors.

• II. To define and describe the toxicities of this regimen in these patients.

SECONDARY OBJECTIVES:

• I. To preliminarily define the antitumor activity of this regimen within the confines of a phase I study.

• II. To characterize the pharmacokinetic parameters of vorinostat in these patients.

• III. To determine whether acetylated histones in peripheral blood mononuclear cells can be identified as a surrogate marker of the biologic effect of vorinostat at various treatment doses.

• IV. To assess the feasibility of collecting and analyzing serum DNA for methylation of the MGMT promoter and describe the relationship between promoter methylation and clinical responses within the confines of this phase I study.

OUTLINE: This is a multicenter, dose-escalation study of vorinostat. Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo blood sample collection periodically for pharmacokinetic and correlative laboratory studies by western blotting and MGMT promoter methylation assays. After completion of study therapy, patients are followed up for 30 days.

Arms

Experimental: Arm I

Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

Interventions

Drug: - vorinostat

Drug: - temozolomide

Other: - diagnostic laboratory biomarker analysis

Other: - pharmacological study